nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—BRAF—colon cancer	0.497	1	CbGaD
Vemurafenib—ABCC1—Irinotecan—colon cancer	0.0517	0.158	CbGbCtD
Vemurafenib—ABCC1—Vincristine—colon cancer	0.0452	0.138	CbGbCtD
Vemurafenib—ABCG2—Irinotecan—colon cancer	0.0346	0.106	CbGbCtD
Vemurafenib—ABCG2—Fluorouracil—colon cancer	0.0332	0.101	CbGbCtD
Vemurafenib—ABCG2—Vincristine—colon cancer	0.0302	0.0923	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—colon cancer	0.0274	0.0835	CbGbCtD
Vemurafenib—ALB—Irinotecan—colon cancer	0.0239	0.0728	CbGbCtD
Vemurafenib—ALB—Fluorouracil—colon cancer	0.0229	0.0699	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—colon cancer	0.0183	0.0559	CbGbCtD
Vemurafenib—CYP1A2—Fluorouracil—colon cancer	0.0137	0.0418	CbGbCtD
Vemurafenib—ALB—Methotrexate—colon cancer	0.0126	0.0385	CbGbCtD
Vemurafenib—CYP3A4—Irinotecan—colon cancer	0.00748	0.0228	CbGbCtD
Vemurafenib—CYP3A4—Vincristine—colon cancer	0.00653	0.0199	CbGbCtD
Vemurafenib—Palmar erythema—Capecitabine—colon cancer	0.00647	0.113	CcSEcCtD
Vemurafenib—ORM1—bile—colon cancer	0.00527	0.195	CbGeAlD
Vemurafenib—Actinic keratosis—Capecitabine—colon cancer	0.00468	0.0816	CcSEcCtD
Vemurafenib—Seborrhoeic keratosis—Capecitabine—colon cancer	0.00372	0.0648	CcSEcCtD
Vemurafenib—RAF1—Topotecan—Irinotecan—colon cancer	0.00316	1	CbGdCrCtD
Vemurafenib—ORM1—gall bladder—colon cancer	0.00146	0.0541	CbGeAlD
Vemurafenib—VIIth nerve paralysis—Vincristine—colon cancer	0.00146	0.0254	CcSEcCtD
Vemurafenib—Hyperkeratosis—Capecitabine—colon cancer	0.00136	0.0238	CcSEcCtD
Vemurafenib—RAF1—embryo—colon cancer	0.00134	0.0496	CbGeAlD
Vemurafenib—ALB—gall bladder—colon cancer	0.00128	0.0474	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—colon cancer	0.00119	1	CrCbGaD
Vemurafenib—BRAF—bone marrow—colon cancer	0.00115	0.0426	CbGeAlD
Vemurafenib—BRAF—vagina—colon cancer	0.00111	0.0408	CbGeAlD
Vemurafenib—RAF1—epithelium—colon cancer	0.0011	0.0405	CbGeAlD
Vemurafenib—RAF1—smooth muscle tissue—colon cancer	0.00106	0.039	CbGeAlD
Vemurafenib—RAF1—renal system—colon cancer	0.00102	0.0376	CbGeAlD
Vemurafenib—Sunburn—Methotrexate—colon cancer	0.000961	0.0168	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Capecitabine—colon cancer	0.00095	0.0166	CcSEcCtD
Vemurafenib—BRAF—liver—colon cancer	0.000933	0.0345	CbGeAlD
Vemurafenib—Paralysis—Vincristine—colon cancer	0.000861	0.015	CcSEcCtD
Vemurafenib—RAF1—lymphoid tissue—colon cancer	0.000845	0.0312	CbGeAlD
Vemurafenib—RAF1—digestive system—colon cancer	0.000834	0.0308	CbGeAlD
Vemurafenib—RAF1—bone marrow—colon cancer	0.000769	0.0284	CbGeAlD
Vemurafenib—RAF1—vagina—colon cancer	0.000737	0.0272	CbGeAlD
Vemurafenib—BRAF—lymph node—colon cancer	0.000715	0.0264	CbGeAlD
Vemurafenib—Neoplasm malignant—Irinotecan—colon cancer	0.000682	0.0119	CcSEcCtD
Vemurafenib—RAF1—liver—colon cancer	0.000622	0.023	CbGeAlD
Vemurafenib—Musculoskeletal pain—Vincristine—colon cancer	0.000605	0.0106	CcSEcCtD
Vemurafenib—ORM1—bone marrow—colon cancer	0.000531	0.0196	CbGeAlD
Vemurafenib—Neoplasm—Irinotecan—colon cancer	0.000527	0.00919	CcSEcCtD
Vemurafenib—Rash maculo-papular—Fluorouracil—colon cancer	0.000507	0.00885	CcSEcCtD
Vemurafenib—Hepatotoxicity—Capecitabine—colon cancer	0.000505	0.00881	CcSEcCtD
Vemurafenib—Rigors—Capecitabine—colon cancer	0.000478	0.00833	CcSEcCtD
Vemurafenib—Polyp—Methotrexate—colon cancer	0.000477	0.00832	CcSEcCtD
Vemurafenib—RAF1—lymph node—colon cancer	0.000477	0.0176	CbGeAlD
Vemurafenib—Folliculitis—Methotrexate—colon cancer	0.000462	0.00806	CcSEcCtD
Vemurafenib—Photosensitivity—Fluorouracil—colon cancer	0.000461	0.00805	CcSEcCtD
Vemurafenib—Pain in extremity—Vincristine—colon cancer	0.000434	0.00758	CcSEcCtD
Vemurafenib—Cyst—Methotrexate—colon cancer	0.000434	0.00757	CcSEcCtD
Vemurafenib—ORM1—liver—colon cancer	0.000429	0.0158	CbGeAlD
Vemurafenib—Paralysis—Methotrexate—colon cancer	0.000418	0.00729	CcSEcCtD
Vemurafenib—CYP1A2—renal system—colon cancer	0.000405	0.015	CbGeAlD
Vemurafenib—ALB—liver—colon cancer	0.000376	0.0139	CbGeAlD
Vemurafenib—Hepatotoxicity—Methotrexate—colon cancer	0.000376	0.00656	CcSEcCtD
Vemurafenib—Dry skin—Fluorouracil—colon cancer	0.000371	0.00648	CcSEcCtD
Vemurafenib—ABCC1—vagina—colon cancer	0.000368	0.0136	CbGeAlD
Vemurafenib—Neoplasm—Capecitabine—colon cancer	0.000353	0.00615	CcSEcCtD
Vemurafenib—Eosinophilia—Fluorouracil—colon cancer	0.000347	0.00605	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Vincristine—colon cancer	0.000343	0.00598	CcSEcCtD
Vemurafenib—Weight decreased—Vincristine—colon cancer	0.00034	0.00592	CcSEcCtD
Vemurafenib—CYP1A2—digestive system—colon cancer	0.000332	0.0123	CbGeAlD
Vemurafenib—Weight decreased—Irinotecan—colon cancer	0.000331	0.00577	CcSEcCtD
Vemurafenib—ORM1—lymph node—colon cancer	0.000329	0.0122	CbGeAlD
Vemurafenib—Neuropathy peripheral—Vincristine—colon cancer	0.000328	0.00572	CcSEcCtD
Vemurafenib—Photosensitivity—Capecitabine—colon cancer	0.000322	0.00562	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Fluorouracil—colon cancer	0.00032	0.00557	CcSEcCtD
Vemurafenib—ABCG2—bone marrow—colon cancer	0.000318	0.0118	CbGeAlD
Vemurafenib—Infestation NOS—Fluorouracil—colon cancer	0.000312	0.00545	CcSEcCtD
Vemurafenib—Infestation—Fluorouracil—colon cancer	0.000312	0.00545	CcSEcCtD
Vemurafenib—ABCC1—liver—colon cancer	0.000311	0.0115	CbGeAlD
Vemurafenib—Neuropathy peripheral—Fluorouracil—colon cancer	0.000306	0.00534	CcSEcCtD
Vemurafenib—ABCG2—vagina—colon cancer	0.000305	0.0113	CbGeAlD
Vemurafenib—Atrial fibrillation—Capecitabine—colon cancer	0.000299	0.00521	CcSEcCtD
Vemurafenib—Vasculitis—Methotrexate—colon cancer	0.000297	0.00519	CcSEcCtD
Vemurafenib—Connective tissue disorder—Vincristine—colon cancer	0.000295	0.00515	CcSEcCtD
Vemurafenib—CYP3A4—renal system—colon cancer	0.000293	0.0108	CbGeAlD
Vemurafenib—Arthritis—Capecitabine—colon cancer	0.000291	0.00508	CcSEcCtD
Vemurafenib—ALB—lymph node—colon cancer	0.000288	0.0107	CbGeAlD
Vemurafenib—CYP2D6—renal system—colon cancer	0.000288	0.0107	CbGeAlD
Vemurafenib—Connective tissue disorder—Irinotecan—colon cancer	0.000287	0.00502	CcSEcCtD
Vemurafenib—Pain in extremity—Capecitabine—colon cancer	0.000283	0.00494	CcSEcCtD
Vemurafenib—Cardiac disorder—Vincristine—colon cancer	0.000279	0.00486	CcSEcCtD
Vemurafenib—Angiopathy—Vincristine—colon cancer	0.000273	0.00475	CcSEcCtD
Vemurafenib—Cardiac disorder—Irinotecan—colon cancer	0.000272	0.00474	CcSEcCtD
Vemurafenib—Mediastinal disorder—Vincristine—colon cancer	0.000271	0.00472	CcSEcCtD
Vemurafenib—Alopecia—Vincristine—colon cancer	0.000265	0.00463	CcSEcCtD
Vemurafenib—Angiopathy—Irinotecan—colon cancer	0.000265	0.00463	CcSEcCtD
Vemurafenib—Mediastinal disorder—Irinotecan—colon cancer	0.000264	0.0046	CcSEcCtD
Vemurafenib—Chills—Irinotecan—colon cancer	0.000262	0.00458	CcSEcCtD
Vemurafenib—Neoplasm—Methotrexate—colon cancer	0.000262	0.00458	CcSEcCtD
Vemurafenib—Dry skin—Capecitabine—colon cancer	0.000259	0.00453	CcSEcCtD
Vemurafenib—Alopecia—Irinotecan—colon cancer	0.000259	0.00451	CcSEcCtD
Vemurafenib—ABCG2—liver—colon cancer	0.000257	0.0095	CbGeAlD
Vemurafenib—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000255	0.00445	CcSEcCtD
Vemurafenib—Back pain—Vincristine—colon cancer	0.000253	0.00441	CcSEcCtD
Vemurafenib—Alopecia—Fluorouracil—colon cancer	0.000248	0.00432	CcSEcCtD
Vemurafenib—CYP1A2—liver—colon cancer	0.000247	0.00914	CbGeAlD
Vemurafenib—Back pain—Irinotecan—colon cancer	0.000246	0.0043	CcSEcCtD
Vemurafenib—Erythema—Fluorouracil—colon cancer	0.000244	0.00426	CcSEcCtD
Vemurafenib—CYP3A4—digestive system—colon cancer	0.00024	0.00888	CbGeAlD
Vemurafenib—Photosensitivity—Methotrexate—colon cancer	0.00024	0.00419	CcSEcCtD
Vemurafenib—ABCC1—lymph node—colon cancer	0.000238	0.0088	CbGeAlD
Vemurafenib—CYP2D6—digestive system—colon cancer	0.000237	0.00874	CbGeAlD
Vemurafenib—Photosensitivity reaction—Capecitabine—colon cancer	0.000223	0.0039	CcSEcCtD
Vemurafenib—Myalgia—Vincristine—colon cancer	0.000223	0.00388	CcSEcCtD
Vemurafenib—Cough—Irinotecan—colon cancer	0.000222	0.00388	CcSEcCtD
Vemurafenib—Weight decreased—Capecitabine—colon cancer	0.000221	0.00386	CcSEcCtD
Vemurafenib—Infestation NOS—Capecitabine—colon cancer	0.000218	0.00381	CcSEcCtD
Vemurafenib—Infestation—Capecitabine—colon cancer	0.000218	0.00381	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000216	0.00377	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Capecitabine—colon cancer	0.000214	0.00373	CcSEcCtD
Vemurafenib—Anaphylactic shock—Vincristine—colon cancer	0.000213	0.00372	CcSEcCtD
Vemurafenib—Infection—Vincristine—colon cancer	0.000212	0.0037	CcSEcCtD
Vemurafenib—Nervous system disorder—Vincristine—colon cancer	0.000209	0.00365	CcSEcCtD
Vemurafenib—Anaphylactic shock—Irinotecan—colon cancer	0.000208	0.00363	CcSEcCtD
Vemurafenib—Myalgia—Fluorouracil—colon cancer	0.000208	0.00362	CcSEcCtD
Vemurafenib—Infection—Irinotecan—colon cancer	0.000206	0.0036	CcSEcCtD
Vemurafenib—Nervous system disorder—Irinotecan—colon cancer	0.000204	0.00356	CcSEcCtD
Vemurafenib—Hypotension—Vincristine—colon cancer	0.000199	0.00348	CcSEcCtD
Vemurafenib—Anaphylactic shock—Fluorouracil—colon cancer	0.000199	0.00347	CcSEcCtD
Vemurafenib—Infection—Fluorouracil—colon cancer	0.000198	0.00345	CcSEcCtD
Vemurafenib—ABCG2—lymph node—colon cancer	0.000197	0.00728	CbGeAlD
Vemurafenib—Nervous system disorder—Fluorouracil—colon cancer	0.000195	0.00341	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000194	0.00339	CcSEcCtD
Vemurafenib—Hypotension—Irinotecan—colon cancer	0.000194	0.00339	CcSEcCtD
Vemurafenib—Oedema peripheral—Capecitabine—colon cancer	0.000193	0.00336	CcSEcCtD
Vemurafenib—Connective tissue disorder—Capecitabine—colon cancer	0.000192	0.00336	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00019	0.00331	CcSEcCtD
Vemurafenib—Hypotension—Fluorouracil—colon cancer	0.000186	0.00325	CcSEcCtD
Vemurafenib—Decreased appetite—Vincristine—colon cancer	0.000186	0.00324	CcSEcCtD
Vemurafenib—Erythema multiforme—Capecitabine—colon cancer	0.000185	0.00323	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Vincristine—colon cancer	0.000184	0.00321	CcSEcCtD
Vemurafenib—Fatigue—Vincristine—colon cancer	0.000184	0.00321	CcSEcCtD
Vemurafenib—Eye disorder—Capecitabine—colon cancer	0.000183	0.00319	CcSEcCtD
Vemurafenib—Constipation—Vincristine—colon cancer	0.000182	0.00318	CcSEcCtD
Vemurafenib—Cardiac disorder—Capecitabine—colon cancer	0.000182	0.00317	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000181	0.00316	CcSEcCtD
Vemurafenib—Decreased appetite—Irinotecan—colon cancer	0.000181	0.00315	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—colon cancer	0.00018	0.00315	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000179	0.00313	CcSEcCtD
Vemurafenib—Fatigue—Irinotecan—colon cancer	0.000179	0.00313	CcSEcCtD
Vemurafenib—CYP3A4—liver—colon cancer	0.000179	0.00662	CbGeAlD
Vemurafenib—Constipation—Irinotecan—colon cancer	0.000178	0.0031	CcSEcCtD
Vemurafenib—Angiopathy—Capecitabine—colon cancer	0.000178	0.0031	CcSEcCtD
Vemurafenib—Mediastinal disorder—Capecitabine—colon cancer	0.000176	0.00308	CcSEcCtD
Vemurafenib—CYP2D6—liver—colon cancer	0.000176	0.00651	CbGeAlD
Vemurafenib—Chills—Capecitabine—colon cancer	0.000176	0.00306	CcSEcCtD
Vemurafenib—Decreased appetite—Fluorouracil—colon cancer	0.000173	0.00302	CcSEcCtD
Vemurafenib—Alopecia—Capecitabine—colon cancer	0.000173	0.00302	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000172	0.003	CcSEcCtD
Vemurafenib—Malnutrition—Capecitabine—colon cancer	0.00017	0.00297	CcSEcCtD
Vemurafenib—Erythema—Capecitabine—colon cancer	0.00017	0.00297	CcSEcCtD
Vemurafenib—Body temperature increased—Vincristine—colon cancer	0.000169	0.00294	CcSEcCtD
Vemurafenib—Dysgeusia—Capecitabine—colon cancer	0.000167	0.00291	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—colon cancer	0.000166	0.0029	CcSEcCtD
Vemurafenib—Back pain—Capecitabine—colon cancer	0.000165	0.00288	CcSEcCtD
Vemurafenib—Body temperature increased—Irinotecan—colon cancer	0.000164	0.00287	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—colon cancer	0.000162	0.00283	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—colon cancer	0.000162	0.00283	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000161	0.00281	CcSEcCtD
Vemurafenib—Body temperature increased—Fluorouracil—colon cancer	0.000157	0.00275	CcSEcCtD
Vemurafenib—Hypersensitivity—Vincristine—colon cancer	0.000157	0.00274	CcSEcCtD
Vemurafenib—Hypersensitivity—Irinotecan—colon cancer	0.000153	0.00267	CcSEcCtD
Vemurafenib—Asthenia—Vincristine—colon cancer	0.000153	0.00267	CcSEcCtD
Vemurafenib—Asthenia—Irinotecan—colon cancer	0.000149	0.0026	CcSEcCtD
Vemurafenib—Cough—Capecitabine—colon cancer	0.000149	0.00259	CcSEcCtD
Vemurafenib—Hypersensitivity—Fluorouracil—colon cancer	0.000147	0.00256	CcSEcCtD
Vemurafenib—Diarrhoea—Vincristine—colon cancer	0.000146	0.00255	CcSEcCtD
Vemurafenib—Arthralgia—Capecitabine—colon cancer	0.000145	0.00253	CcSEcCtD
Vemurafenib—Myalgia—Capecitabine—colon cancer	0.000145	0.00253	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000144	0.00251	CcSEcCtD
Vemurafenib—Diarrhoea—Irinotecan—colon cancer	0.000142	0.00248	CcSEcCtD
Vemurafenib—Dizziness—Vincristine—colon cancer	0.000141	0.00246	CcSEcCtD
Vemurafenib—Pruritus—Fluorouracil—colon cancer	0.000141	0.00246	CcSEcCtD
Vemurafenib—Infection—Capecitabine—colon cancer	0.000138	0.00241	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—colon cancer	0.000138	0.0024	CcSEcCtD
Vemurafenib—Dizziness—Irinotecan—colon cancer	0.000137	0.0024	CcSEcCtD
Vemurafenib—Nervous system disorder—Capecitabine—colon cancer	0.000136	0.00238	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—colon cancer	0.000136	0.00238	CcSEcCtD
Vemurafenib—Diarrhoea—Fluorouracil—colon cancer	0.000136	0.00238	CcSEcCtD
Vemurafenib—Vomiting—Vincristine—colon cancer	0.000136	0.00237	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—colon cancer	0.000135	0.00236	CcSEcCtD
Vemurafenib—Skin disorder—Capecitabine—colon cancer	0.000135	0.00236	CcSEcCtD
Vemurafenib—Rash—Vincristine—colon cancer	0.000135	0.00235	CcSEcCtD
Vemurafenib—Dermatitis—Vincristine—colon cancer	0.000134	0.00235	CcSEcCtD
Vemurafenib—Headache—Vincristine—colon cancer	0.000134	0.00233	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—colon cancer	0.000132	0.00231	CcSEcCtD
Vemurafenib—Vomiting—Irinotecan—colon cancer	0.000132	0.00231	CcSEcCtD
Vemurafenib—Dizziness—Fluorouracil—colon cancer	0.000132	0.0023	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—colon cancer	0.000131	0.00229	CcSEcCtD
Vemurafenib—Rash—Irinotecan—colon cancer	0.000131	0.00229	CcSEcCtD
Vemurafenib—Dermatitis—Irinotecan—colon cancer	0.000131	0.00228	CcSEcCtD
Vemurafenib—Chills—Methotrexate—colon cancer	0.000131	0.00228	CcSEcCtD
Vemurafenib—Headache—Irinotecan—colon cancer	0.00013	0.00227	CcSEcCtD
Vemurafenib—Hypotension—Capecitabine—colon cancer	0.00013	0.00227	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—colon cancer	0.000129	0.00225	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—colon cancer	0.000127	0.00221	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—colon cancer	0.000127	0.00221	CcSEcCtD
Vemurafenib—Nausea—Vincristine—colon cancer	0.000127	0.00221	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000127	0.00221	CcSEcCtD
Vemurafenib—Vomiting—Fluorouracil—colon cancer	0.000127	0.00221	CcSEcCtD
Vemurafenib—Rash—Fluorouracil—colon cancer	0.000126	0.00219	CcSEcCtD
Vemurafenib—Dermatitis—Fluorouracil—colon cancer	0.000125	0.00219	CcSEcCtD
Vemurafenib—Headache—Fluorouracil—colon cancer	0.000125	0.00218	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—colon cancer	0.000124	0.00217	CcSEcCtD
Vemurafenib—Nausea—Irinotecan—colon cancer	0.000123	0.00215	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—colon cancer	0.000123	0.00214	CcSEcCtD
Vemurafenib—Decreased appetite—Capecitabine—colon cancer	0.000121	0.00211	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Capecitabine—colon cancer	0.00012	0.0021	CcSEcCtD
Vemurafenib—Fatigue—Capecitabine—colon cancer	0.00012	0.00209	CcSEcCtD
Vemurafenib—Constipation—Capecitabine—colon cancer	0.000119	0.00208	CcSEcCtD
Vemurafenib—Nausea—Fluorouracil—colon cancer	0.000118	0.00206	CcSEcCtD
Vemurafenib—Cough—Methotrexate—colon cancer	0.000111	0.00193	CcSEcCtD
Vemurafenib—Body temperature increased—Capecitabine—colon cancer	0.00011	0.00192	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—colon cancer	0.000108	0.00188	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—colon cancer	0.000108	0.00188	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000107	0.00187	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—colon cancer	0.000104	0.00181	CcSEcCtD
Vemurafenib—Infection—Methotrexate—colon cancer	0.000103	0.00179	CcSEcCtD
Vemurafenib—Hypersensitivity—Capecitabine—colon cancer	0.000102	0.00179	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—colon cancer	0.000102	0.00177	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—colon cancer	0.000101	0.00175	CcSEcCtD
Vemurafenib—Asthenia—Capecitabine—colon cancer	9.98e-05	0.00174	CcSEcCtD
Vemurafenib—Pruritus—Capecitabine—colon cancer	9.84e-05	0.00172	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—colon cancer	9.68e-05	0.00169	CcSEcCtD
Vemurafenib—Diarrhoea—Capecitabine—colon cancer	9.52e-05	0.00166	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—colon cancer	9.43e-05	0.00165	CcSEcCtD
Vemurafenib—Dizziness—Capecitabine—colon cancer	9.2e-05	0.0016	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—colon cancer	9e-05	0.00157	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—colon cancer	8.94e-05	0.00156	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—colon cancer	8.93e-05	0.00156	CcSEcCtD
Vemurafenib—Vomiting—Capecitabine—colon cancer	8.84e-05	0.00154	CcSEcCtD
Vemurafenib—Rash—Capecitabine—colon cancer	8.77e-05	0.00153	CcSEcCtD
Vemurafenib—Dermatitis—Capecitabine—colon cancer	8.76e-05	0.00153	CcSEcCtD
Vemurafenib—Headache—Capecitabine—colon cancer	8.71e-05	0.00152	CcSEcCtD
Vemurafenib—Nausea—Capecitabine—colon cancer	8.26e-05	0.00144	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—colon cancer	8.19e-05	0.00143	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—colon cancer	7.63e-05	0.00133	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—colon cancer	7.43e-05	0.0013	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—colon cancer	7.33e-05	0.00128	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—colon cancer	7.09e-05	0.00124	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—colon cancer	6.85e-05	0.00119	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—colon cancer	6.58e-05	0.00115	CcSEcCtD
Vemurafenib—Rash—Methotrexate—colon cancer	6.53e-05	0.00114	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—colon cancer	6.52e-05	0.00114	CcSEcCtD
Vemurafenib—Headache—Methotrexate—colon cancer	6.49e-05	0.00113	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—colon cancer	6.15e-05	0.00107	CcSEcCtD
Vemurafenib—RAF1—Signaling by NGF—NRAS—colon cancer	2.22e-05	0.000258	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	2.21e-05	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—AKT1—colon cancer	2.2e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—HRAS—colon cancer	2.16e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	2.16e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	2.11e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—AKT1—colon cancer	2.11e-05	0.000244	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	2.11e-05	0.000244	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—AKT1—colon cancer	2.11e-05	0.000244	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—SRC—colon cancer	2.09e-05	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—AKT1—colon cancer	2.09e-05	0.000242	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.08e-05	0.000241	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—AKT1—colon cancer	2.07e-05	0.000241	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—AKT1—colon cancer	2.07e-05	0.00024	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—AKT1—colon cancer	2.06e-05	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	2.04e-05	0.000237	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—colon cancer	2.04e-05	0.000236	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—colon cancer	2.02e-05	0.000235	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—NRAS—colon cancer	2.01e-05	0.000233	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—AKT1—colon cancer	1.99e-05	0.000231	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.98e-05	0.00023	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—KRAS—colon cancer	1.94e-05	0.000226	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KRAS—colon cancer	1.91e-05	0.000222	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CHST5—colon cancer	1.91e-05	0.000222	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ODC1—colon cancer	1.91e-05	0.000222	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDH1—colon cancer	1.9e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	1.87e-05	0.000217	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—colon cancer	1.83e-05	0.000213	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FGFR3—colon cancer	1.82e-05	0.000211	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—PIK3CA—colon cancer	1.79e-05	0.000207	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.76e-05	0.000205	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—PIK3CA—colon cancer	1.76e-05	0.000204	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—KRAS—colon cancer	1.73e-05	0.000201	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APC—colon cancer	1.67e-05	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—colon cancer	1.66e-05	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—colon cancer	1.66e-05	0.000192	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—colon cancer	1.65e-05	0.000192	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CTNNB1—colon cancer	1.65e-05	0.000191	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.63e-05	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—colon cancer	1.63e-05	0.000189	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	1.54e-05	0.000179	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EP300—colon cancer	1.53e-05	0.000178	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	1.53e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—EP300—colon cancer	1.5e-05	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—SRC—colon cancer	1.49e-05	0.000173	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	1.49e-05	0.000173	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ODC1—colon cancer	1.47e-05	0.000171	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CHST5—colon cancer	1.47e-05	0.000171	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—colon cancer	1.47e-05	0.000171	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SRC—colon cancer	1.46e-05	0.00017	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CTNNB1—colon cancer	1.46e-05	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—colon cancer	1.45e-05	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—AKT1—colon cancer	1.44e-05	0.000167	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NRAS—colon cancer	1.43e-05	0.000167	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—colon cancer	1.43e-05	0.000165	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CDKN1A—colon cancer	1.42e-05	0.000165	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL2L1—colon cancer	1.42e-05	0.000165	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NRAS—colon cancer	1.41e-05	0.000163	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDKN1A—colon cancer	1.37e-05	0.000159	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	1.37e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGFR3—colon cancer	1.36e-05	0.000158	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.36e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EP300—colon cancer	1.35e-05	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—colon cancer	1.33e-05	0.000155	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ABCB1—colon cancer	1.33e-05	0.000154	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—SRC—colon cancer	1.32e-05	0.000153	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—colon cancer	1.31e-05	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—colon cancer	1.31e-05	0.000152	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TYMS—colon cancer	1.3e-05	0.000151	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGFR3—colon cancer	1.27e-05	0.000148	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NRAS—colon cancer	1.27e-05	0.000147	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—colon cancer	1.27e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—SRC—colon cancer	1.26e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGFR3—colon cancer	1.26e-05	0.000146	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGFR3—colon cancer	1.25e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—KRAS—colon cancer	1.23e-05	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NRAS—colon cancer	1.22e-05	0.000141	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—KRAS—colon cancer	1.21e-05	0.000141	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ABCB1—colon cancer	1.17e-05	0.000136	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APC—colon cancer	1.17e-05	0.000135	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.16e-05	0.000135	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—colon cancer	1.15e-05	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APC—colon cancer	1.15e-05	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDH1—colon cancer	1.15e-05	0.000133	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TYMS—colon cancer	1.15e-05	0.000133	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APC—colon cancer	1.14e-05	0.000133	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CTNNB1—colon cancer	1.13e-05	0.000131	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.13e-05	0.000131	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PIK3CA—colon cancer	1.11e-05	0.000129	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—colon cancer	1.11e-05	0.000129	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CDKN1A—colon cancer	1.11e-05	0.000128	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—colon cancer	1.09e-05	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Disease—BRAF—colon cancer	1.08e-05	0.000126	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—colon cancer	1.08e-05	0.000125	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—BRAF—colon cancer	1.07e-05	0.000125	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EP300—colon cancer	1.05e-05	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—colon cancer	1.05e-05	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—colon cancer	1.05e-05	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—colon cancer	1.03e-05	0.00012	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SRC—colon cancer	1.02e-05	0.000119	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1e-05	0.000117	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PIK3CA—colon cancer	1e-05	0.000116	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NRAS—colon cancer	9.85e-06	0.000114	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PIK3CA—colon cancer	9.62e-06	0.000112	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	9.49e-06	0.00011	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—colon cancer	9.27e-06	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—colon cancer	9.27e-06	0.000108	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—colon cancer	9.24e-06	0.000107	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—colon cancer	9.17e-06	0.000106	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—colon cancer	9.15e-06	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—colon cancer	9.09e-06	0.000106	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—colon cancer	8.97e-06	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—colon cancer	8.9e-06	0.000103	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.86e-06	0.000103	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGFR3—colon cancer	8.8e-06	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—colon cancer	8.76e-06	0.000102	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—colon cancer	8.68e-06	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTNNB1—colon cancer	8.49e-06	9.85e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—colon cancer	8.48e-06	9.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1A—colon cancer	8.29e-06	9.62e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—colon cancer	8.23e-06	9.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—colon cancer	8.19e-06	9.5e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—colon cancer	8.13e-06	9.44e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—EP300—colon cancer	8.1e-06	9.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APC—colon cancer	8.08e-06	9.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—colon cancer	8.08e-06	9.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—colon cancer	8.01e-06	9.3e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CTNNB1—colon cancer	7.93e-06	9.21e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EP300—colon cancer	7.89e-06	9.16e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.88e-06	9.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—colon cancer	7.87e-06	9.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—colon cancer	7.86e-06	9.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CTNNB1—colon cancer	7.84e-06	9.09e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—colon cancer	7.79e-06	9.04e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CTNNB1—colon cancer	7.77e-06	9.01e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1A—colon cancer	7.75e-06	8.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—colon cancer	7.67e-06	8.9e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—colon cancer	7.67e-06	8.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1A—colon cancer	7.66e-06	8.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BRAF—colon cancer	7.59e-06	8.81e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1A—colon cancer	7.59e-06	8.81e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—colon cancer	7.58e-06	8.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—colon cancer	7.38e-06	8.57e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EP300—colon cancer	7.37e-06	8.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.37e-06	8.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—colon cancer	7.36e-06	8.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EP300—colon cancer	7.28e-06	8.45e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—colon cancer	7.27e-06	8.44e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EP300—colon cancer	7.22e-06	8.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—colon cancer	7.21e-06	8.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—colon cancer	7.21e-06	8.36e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—colon cancer	7.17e-06	8.32e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TYMS—colon cancer	7.08e-06	8.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—colon cancer	7.08e-06	8.22e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—colon cancer	7.04e-06	8.17e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—colon cancer	7.02e-06	8.15e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—colon cancer	6.98e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—colon cancer	6.95e-06	8.07e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—colon cancer	6.9e-06	8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—colon cancer	6.81e-06	7.91e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—colon cancer	6.75e-06	7.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—colon cancer	6.72e-06	7.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—colon cancer	6.52e-06	7.57e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—colon cancer	6.42e-06	7.46e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—colon cancer	6.41e-06	7.44e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—colon cancer	6.4e-06	7.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—colon cancer	6.39e-06	7.41e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—colon cancer	6.36e-06	7.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—colon cancer	6.35e-06	7.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—colon cancer	6.35e-06	7.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—colon cancer	6.33e-06	7.35e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—colon cancer	6.29e-06	7.3e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—colon cancer	6.28e-06	7.29e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—colon cancer	6.28e-06	7.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—colon cancer	6.21e-06	7.2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.2e-06	7.2e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—colon cancer	6.15e-06	7.14e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—EP300—colon cancer	6.05e-06	7.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—colon cancer	5.99e-06	6.95e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—colon cancer	5.96e-06	6.91e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—colon cancer	5.94e-06	6.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—colon cancer	5.91e-06	6.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—colon cancer	5.87e-06	6.81e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMS—colon cancer	5.85e-06	6.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—colon cancer	5.84e-06	6.77e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—colon cancer	5.81e-06	6.75e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—colon cancer	5.8e-06	6.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—colon cancer	5.69e-06	6.61e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—colon cancer	5.54e-06	6.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—colon cancer	5.54e-06	6.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—colon cancer	5.49e-06	6.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—colon cancer	5.45e-06	6.33e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.45e-06	6.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—colon cancer	5.4e-06	6.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—colon cancer	5.39e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—colon cancer	5.36e-06	6.22e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—colon cancer	5.34e-06	6.2e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—EP300—colon cancer	5.32e-06	6.17e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—colon cancer	5.28e-06	6.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—colon cancer	5.22e-06	6.06e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.16e-06	5.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EP300—colon cancer	5.1e-06	5.92e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—colon cancer	5.05e-06	5.86e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—colon cancer	5.05e-06	5.86e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—colon cancer	5.02e-06	5.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—colon cancer	4.99e-06	5.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—colon cancer	4.96e-06	5.76e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMS—colon cancer	4.96e-06	5.75e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—colon cancer	4.94e-06	5.73e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—colon cancer	4.89e-06	5.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—colon cancer	4.83e-06	5.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—colon cancer	4.77e-06	5.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—colon cancer	4.77e-06	5.53e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—colon cancer	4.47e-06	5.19e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—colon cancer	4.46e-06	5.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—colon cancer	4.45e-06	5.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—colon cancer	4.43e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—colon cancer	4.4e-06	5.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—colon cancer	4.36e-06	5.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—colon cancer	4.35e-06	5.05e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—colon cancer	4.14e-06	4.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—colon cancer	4.11e-06	4.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—colon cancer	3.95e-06	4.58e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—colon cancer	3.94e-06	4.57e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—colon cancer	3.89e-06	4.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMS—colon cancer	3.82e-06	4.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.81e-06	4.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—colon cancer	3.77e-06	4.38e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—colon cancer	3.65e-06	4.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—colon cancer	3.65e-06	4.24e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—colon cancer	3.51e-06	4.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—colon cancer	3.49e-06	4.05e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—EP300—colon cancer	3.28e-06	3.81e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—colon cancer	3.26e-06	3.78e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—colon cancer	3.22e-06	3.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—colon cancer	3.08e-06	3.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—colon cancer	2.76e-06	3.2e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—EP300—colon cancer	2.71e-06	3.15e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—colon cancer	2.71e-06	3.14e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—colon cancer	2.43e-06	2.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—EP300—colon cancer	2.3e-06	2.67e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—colon cancer	2.13e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—colon cancer	2.01e-06	2.33e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—colon cancer	1.98e-06	2.3e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—EP300—colon cancer	1.77e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—colon cancer	1.7e-06	1.97e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—colon cancer	1.64e-06	1.9e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—colon cancer	1.39e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—colon cancer	1.31e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—colon cancer	1.07e-06	1.24e-05	CbGpPWpGaD
